Clinical Trial Update: Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of cetuximab and dasatinib in recurrent squamous cell carcinoma of the head and neck was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• DASATINIB (Dasatinib)

Snippet

Sponsor: Julie E. Bauman, MD, MPH | Conditions: Squamous Cell Carcinoma Of The Head And Neck | Phase 2 | Status: TERMINATED | Results posted: 2018-01-05